tirzepatide stroke UC Irvine researchers project cardiac benefits from weight-loss medication Early use of tirzepatide after

Key safety observations from Phase 2 data include: Gastrointestinal side effects were the most commonly reported adverse events Dose-dependent tolerability issues were noted, particularly at higher doses, with meaningful discontinuation rates Increases in heart rate were observed, consistent with the known class effect of GLP-1 receptor agonists

Mathew, S

Pharmacologic screening identifies metabolic vulnerabilities of CD8(+) T cells

Foresman, J

Real-world outcomes compiled from medical weight loss clinics show similar patterns with slightly wider ranges

When Should I Contact A Provider About Tirzepatide-Related Diarrhea